OCUL insider transaction filings
OCULAR THERAPEUTIX, INC — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-18. Screen OCUL transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-18 | 4 | Dugel Pravin — See Remarks, Director | Gift (G): 50,092 @ $0 · Gift (G): 50,092 @ $0 | EDGAR |
| 2026-06-12 | 4 | Robins Jason Shand — Chief Financial Officer | Grant/award (A): 15,441 @ $0 · Grant/award (A): 14,024 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Hong Seung Suh — Director | Grant/award (A): 14,000 @ $0 · Grant/award (A): 44,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Williams Leslie J. — Director | Grant/award (A): 14,000 @ $0 · Grant/award (A): 44,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Warden Charles M — Director | Grant/award (A): 14,000 @ $0 · Grant/award (A): 44,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Graves Adrienne L — Director | Grant/award (A): 14,000 @ $0 · Grant/award (A): 44,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | LINDSTROM RICHARD L MD — Director | Grant/award (A): 14,000 @ $0 · Grant/award (A): 44,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | RAINES MERILEE — Director | Grant/award (A): 14,000 @ $0 · Grant/award (A): 44,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Waheed Nadia — Chief Medical Officer | Sale (S): 14,828 @ $8.27 | EDGAR |
| 2026-05-28 | 4 | Dugel Pravin — See Remarks, Director | Sale (S): 21,156 @ $8.20 · Gift (G): 394,696 @ $0 · Gift (G): 394,696 @ $0 | EDGAR |
| 2026-05-28 | 4 | Kaiser Peter — Chief Development Officer | Sale (S): 2,967 @ $8.20 | EDGAR |
| 2026-05-28 | 4 | Heier Jeffrey S. — Chief Scientific Officer | Sale (S): 3,018 @ $8.20 | EDGAR |
| 2026-05-28 | 4 | Nayak Sanjay — Chief Strategy Officer | Sale (S): 1,858 @ $8.20 | EDGAR |
| 2026-04-13 | 4 | Dugel Pravin — See Remarks, Director | Gift (G): 394,696 @ $0 · Gift (G): 394,696 @ $0 | EDGAR |
| 2026-02-25 | 4 | Dugel Pravin — See Remarks, Director | Sale (S): 20,056 @ $8.28 | EDGAR |
| 2026-02-25 | 4 | Kaiser Peter — Chief Development Officer | Sale (S): 2,810 @ $8.28 | EDGAR |
| 2026-02-25 | 4 | Heier Jeffrey S. — Chief Scientific Officer | Sale (S): 3,057 @ $8.28 | EDGAR |
| 2026-02-25 | 4 | Nayak Sanjay — Chief Strategy Officer | Sale (S): 1,759 @ $8.28 | EDGAR |
| 2026-02-24 | 4 | Waheed Nadia — Chief Medical Officer | Sale (S): 3,510 @ $7.74 | EDGAR |
| 2026-02-24 | 4 | LINDSTROM RICHARD L MD — Director | Purchase (P): 60,229 @ $7.66 | EDGAR |
| 2026-02-17 | 4 | Notman Donald — Chief Operating Officer | Sale (S): 11,446 @ $9.04 | EDGAR |
| 2026-02-17 | 4 | Nayak Sanjay — Chief Strategy Officer | Sale (S): 10,348 @ $9.04 | EDGAR |
| 2026-02-17 | 4 | Dugel Pravin — See Remarks, Director | Sale (S): 124,882 @ $9.04 | EDGAR |
| 2026-02-17 | 4 | Waheed Nadia — Chief Medical Officer | Sale (S): 7,863 @ $9.04 | EDGAR |
| 2026-02-04 | 4 | Notman Donald — Chief Operating Officer | Sale (S): 5,455 @ $9.14 · Sale (S): 6,035 @ $8.54 | EDGAR |
| 2026-01-26 | 4 | Robinson David Wayne — Global CCO | Grant/award (A): 136,000 @ $0 · Grant/award (A): 416,000 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | Robins Jason Shand — Interim CFO | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Anderman Todd — Chief Legal Officer | Grant/award (A): 64,900 @ $0 · Grant/award (A): 197,650 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Meyers Steve Lawrence — Chief Commercial Officer | Grant/award (A): 64,900 @ $0 · Grant/award (A): 197,650 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Nayak Sanjay — Chief Strategy Officer | Grant/award (A): 64,900 @ $0 · Grant/award (A): 197,650 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Kaiser Peter — Chief Development Officer | Grant/award (A): 79,112 @ $0 · Grant/award (A): 240,932 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Saroj Namrata — Chief Business Officer | Grant/award (A): 79,112 @ $0 · Grant/award (A): 240,932 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Waheed Nadia — Chief Medical Officer | Grant/award (A): 79,112 @ $0 · Grant/award (A): 240,932 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Heier Jeffrey S. — Chief Scientific Officer | Grant/award (A): 79,112 @ $0 · Grant/award (A): 240,932 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Notman Donald — See Remarks | Grant/award (A): 79,112 @ $0 · Grant/award (A): 240,932 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | Nayak Sanjay — Chief Strategy Officer | Sale (S): 1,878 @ $12.04 | EDGAR |
| 2025-11-26 | 4 | Dugel Pravin — See Remarks, Director | Sale (S): 19,530 @ $12.04 · Gift (G): 49,754 @ $0 · Gift (G): 49,754 @ $0 | EDGAR |
| 2025-11-26 | 4 | Kaiser Peter — Chief Development Officer | Sale (S): 3,007 @ $12.02 | EDGAR |
| 2025-11-26 | 4 | Heier Jeffrey S. — Chief Scientific Officer | Sale (S): 3,469 @ $12.04 | EDGAR |
| 2025-11-07 | 4 | Saroj Namrata — Chief Business Officer | Sale (S): 25,865 @ $10.74 | EDGAR |
| 2025-10-10 | 4 | Anderman Todd — Chief Legal Officer | Sale (S): 11,132 @ $12.34 | EDGAR |
| 2025-10-06 | 4 | Kaiser Peter — Chief Development Officer | Sale (S): 9,653 @ $11.03 | EDGAR |
| 2025-10-06 | 4 | Heier Jeffrey S. — Chief Scientific Officer | Sale (S): 10,502 @ $11.04 | EDGAR |
| 2025-09-11 | 4 | Dugel Pravin — See Remarks, Director | Gift (G): 49,754 @ $0 · Gift (G): 49,754 @ $0 | EDGAR |
| 2025-09-04 | 4 | Notman Donald — See Remarks | Sale (S): 1,066 @ $12.43 | EDGAR |
| 2025-08-27 | 4 | Kaiser Peter — Chief Development Officer | Sale (S): 3,011 @ $12.04 | EDGAR |
| 2025-08-27 | 4 | Nayak Sanjay — Chief Strategy Officer | Sale (S): 1,885 @ $12.04 | EDGAR |
| 2025-08-27 | 4 | Heier Jeffrey S. — Chief Scientific Officer | Sale (S): 3,063 @ $12.04 | EDGAR |
| 2025-08-27 | 4 | Dugel Pravin — See Remarks, Director | Sale (S): 21,494 @ $12.04 | EDGAR |
| 2025-08-14 | 4 | Waheed Nadia — Chief Medical Officer | Grant/award (A): 40,363 @ $0 · Grant/award (A): 122,923 (derivative) @ $0 | EDGAR |
Recent 8-K events — OCULAR THERAPEUTIX, INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-02-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-12-18 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-12-05 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=OCUL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →